Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 3/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866016 | 0.99 | NR5A1 (0.55) | NR5A1RARBLTA4HPTPN11TP53 | |
| SCHEMBL9405815 | 0.99 | NR5A1 (0.55) | NR5A1RARBLTA4HPTPN11TP53 | |
| SCHEMBL8992927 | 0.99 | NR5A1 (0.55) | NR5A1RARBLTA4HPTPN11TP53 | |
| SCHEMBL9419290 | 0.97 | NR5A1 (0.53) | NR5A1RARBLTA4HPTPN11TP53 | |
| SCHEMBL1575262 | 0.94 | MCL1 (0.49) | NR5A1RARBLTA4HPTPN11MCL1 | |
| SCHEMBL9563786 | 0.91 | RARB (0.56) | NR5A1RARBLTA4HPTPN11TP53 | |
| SCHEMBL9563837 | 0.91 | RARB (0.56) | NR5A1RARBLTA4HPTPN11TP53 | |
| SCHEMBL9563731 | 0.91 | RARB (0.56) | NR5A1RARBLTA4HPTPN11TP53 | |
| SCHEMBL9563687 | 0.91 | RARB (0.56) | NR5A1RARBLTA4HPTPN11TP53 | |
| SCHEMBL9563794 | 0.91 | RARB (0.56) | NR5A1RARBLTA4HPTPN11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351452-B2 | Liquid crystalline compounds containing a biphenyl core | QINETIQ LIMITED (GB) | 2008-04-01 | — | — | US | disclosed |
| US-20050001200-A1 | Liquid crystalline compounds containing a biphenyl core | QINETIQ LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| US-6737124-B2 | ESPECIALLY DISILANES | DISPLAYTECH, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20030003245-A1 | Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion | CITIZEN FINETECH MIYOTA CO., LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030003245-A1 | Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion | FFAR3, FFAR1, LPAR1 | NR5A1 379/4885RARB 1133/4885LTA4H 1475/4885 |
| US-20050001200-A1 | Liquid crystalline compounds containing a biphenyl core | YBX1, AFF1, AFF2 | NR5A1 676/4885RARB 1075/4885LTA4H 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.